eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
A phase 3 trial of Ensartinib, Crizotinib in non-small-cell lung cancer and small-cell lung cancer, run by Xcovery Holdings, Inc., active and no longer recruiting.
Overview
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients is a phase 3 interventional study registered as NCT02767804 by Xcovery Holdings, Inc., with 290 participants enrolled, started 2016-06 and due to reach its primary completion in 2025-12-30. Interventions recorded: X-396 (ensartinib), crizotinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Shares Crizotinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares Crizotinib, Non-small-cell lung cancer.
- TrialA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Shares Crizotinib, Non-small-cell lung cancer.
- TargetRON receptor (MST1R)
Shares Crizotinib, Non-small-cell lung cancer.
- TreatmentCapmatinib
Shares Crizotinib, Non-small-cell lung cancer.
- InstitutionUniversity of Colorado Cancer Center
Shares Crizotinib, Non-small-cell lung cancer.
- TargetROS1
Shares Crizotinib, Non-small-cell lung cancer.